In HFrEF, adding empagliflozin to medical therapy...

In HFrEF, adding empagliflozin to medical therapy reduced a composite outcome, regardless of CKD status.

Abstract

SOURCE CITATION: Zannad F, Ferreira JP, Pocock SJ, et al. Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from EMPEROR-Reduced. Circulation. 2021;143:310-21. 33095032.

Authors

Santos-Gallego CG; Van Spall HGC

Journal

Annals of Internal Medicine, Vol. 174, No. 6,

Publisher

American College of Physicians

Publication Date

June 1, 2021

DOI

10.7326/acpj202106150-068

ISSN

1056-8751

Associated Experts

Harriette Van Spall

Associate Professor, Faculty of Health Sciences

Visit profile

Labels